Try our beta test site
16 studies found for:    Open Studies | GVHD AND steroid refractory
Show Display Options
Rank Status Study
1 Recruiting UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Condition: Steroid Refractory Acute Graft Versus Host Disease
Intervention: Drug: UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System
2 Recruiting Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD
Condition: Chronic GVHD After HCT for Cancer or Immune Disease
Intervention: Other: Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.
3 Recruiting Ruxolitinib for Steroid-refractory GVHD
Condition: Graft Vs Host Disease
Intervention: Drug: Ruxolitinib Oral Tablet
4 Recruiting Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions: Other: Treg-enriched infusion;   Drug: Interleukin-2
5 Recruiting A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Condition: Graft-versus-host Disease
Interventions: Drug: Ruxolitinib;   Drug: Prednisone or methylprednisolone
6 Recruiting A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Graft vs Host Disease
Intervention: Biological: Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
7 Recruiting A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host-disease
Interventions: Procedure: Extracorporeal Photopheresis (ECP);   Drug: Interleukin-2
8 Recruiting A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
Condition: Chronic Graft Versus Host Disease
Intervention: Drug: Abatacept
9 Recruiting Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
Condition: Chronic Graft Versus Host Disease
Interventions: Biological: Aldesleukin;   Procedure: Extracorporeal Photopheresis;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
10 Recruiting Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Imatinib mesylate, Mycophenolate mofetil
11 Recruiting Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Hydrogen
12 Not yet recruiting A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Condition: Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: Vedolizumab
13 Not yet recruiting Ruxolitinib In GvHD
Condition: Graft vs Host Disease
Intervention: Drug: Treatment with Ruxolitinib
14 Recruiting Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Condition: Corticosteroid Refractory Acute Graft vs Host Disease
Interventions: Drug: Ruxolitinib;   Drug: Best Available Therapy (BAT)
15 Recruiting A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: KD025
16 Recruiting Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Condition: Chronic Graft Versus Host Disease
Interventions: Drug: ibrutinib;   Drug: Placebo;   Drug: Prednisone

Study has passed its completion date and status has not been verified in more than two years.